Table 1 Baseline characteristics of patients
Baseline characteristics of the study population population (n = 105) | N (%) |
|---|---|
Age, years | |
Mean | 47 |
SUVmean | 3.92 ± 2.05 |
SUVmax | 6.25 ± 3.73 |
SUVmin | 1.63 ± 0.69 |
ER status | |
Positive | 83 (79.05%) |
Negative | 22 (20.95%) |
PR status | |
Positive | 88 (83.8%) |
Negative | 17 (16.2%) |
Ki67 | |
Positive | 83 (79.05%) |
Negative | 22 (20.95%) |
Molecular subtype | |
HR-positive/HER2-negative | 66 (62.29%) |
HER2-positive | 31 (29.52%) |
TNBC | 8 (8.19%) |
Menopausal status | |
Premenopausal | 37 (35.24%) |
Postmenopausal | 68 (64.76%) |
Prechemotherapy T stage | |
T1 | 12 (11.43%) |
T2 | 56 (53.33%) |
T3 | 19 (18.1%) |
T4 | 18 (17.14%) |
Prechemotherapy N stage | |
N0 | 21 (20%) |
N1 | 36 (34.29%) |
N2 | 35 (33.33%) |
N3 | 13 (12.38%) |
Prechemotherapy stage | |
II | 47 (44.76%) |
III | 58 (55.24%) |
Event | |
Yes | 22 (20.95%) |
No | 83 (79.05%) |
RCB | |
I | 15 (14.29%) |
II | 48 (45.71%) |
III | 42 (40%) |